Altered expression of farnesyl pyrophosphate synthase in prostate cancer: Evidence for a role of the mevalonate pathway in disease progression?

World Journal of Urology

Volumn 31, Issue 2, 2013, Pages 345-350

  Todenhöfer, Tilman ^a   Hennenlotter, Jörg ^a   Kühs, Ursula ^a   Gerber, Valentina ^a   Gakis, Georgios ^a   Vogel, Ulrich ^a   Aufderklamm, Stefan ^a   Merseburger, Axel ^b   Knapp, Judith ^c   Stenzl, Arnulf ^a   Schwentner, Christian ^a,d  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^b HANNOVER MEDICAL SCHOOL   (Germany)

^c Diakonieklinikum ^*  (Germany)

^d UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

Bisphosphonates; Farnesyl pyrophosphate synthase; Mevalonate pathway; Prostate cancer; Zoledronic acid

Indexed keywords

EID: 84876423480     PISSN: 07244983     EISSN: 14338726     Source Type: Journal    
DOI: 10.1007/s00345-012-0844-y     Document Type: Article

References (30)

1. Roy M, Kung HJ, Ghosh PM (2011) Statins and prostate cancer: role of cholesterol inhibition versus prevention of small GTP-binding proteins. Am J Cancer Res 1(4): 542-561.
2. Russell RG (2011) Bisphosphonates: the first 40 years. Bone 49(1): 2-19. doi: 10. 1016/j. bone. 2011. 04. 022.
3. Luckman SP, Hughes DE, Coxon FP, Graham R, Russell G, Rogers MJ (1998) Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras. J Bone Miner Res 13(4): 581-589. doi: 10. 1359/jbmr. 1998. 13. 4. 581.
4. Clezardin P (2011) Bisphosphonates' antitumor activity: an unravelled side of a multifaceted drug class. Bone 48(1): 71-79. doi: 10. 1016/j. bone. 2010. 07. 016.
5. Farley SJ (2010) Prostate cancer: time to trial statins? Nat Rev Urol 7(7): 359. doi: 10. 1038/nrurol. 2010. 85.
6. Saylor PJ, Lee RJ, Smith MR (2011) Emerging therapies to prevent skeletal morbidity in men with prostate cancer. J Clin Oncol 29(27): 3705-3714. doi: 10. 1200/JCO. 2010. 34. 4994.
7. Coxon JP, Oades GM, Kirby RS, Colston KW (2004) Zoledronic acid induces apoptosis and inhibits adhesion to mineralized matrix in prostate cancer cells via inhibition of protein prenylation. BJU Int 94(1): 164-170. doi: 10. 1111/j. 1464-4096. 2004. 04831. xBJU4831.
8. Jacobs EJ, Rodriguez C, Bain EB, Wang Y, Thun MJ, Calle EE (2007) Cholesterol-lowering drugs and advanced prostate cancer incidence in a large US cohort. Cancer Epidemiol Biomarkers Prev 16(11): 2213-2217. doi: 10. 1158/1055-9965. EPI-07-0448.
9. Hamilton RJ, Banez LL, Aronson WJ, Terris MK, Platz EA, Kane CJ, Presti JC Jr, Amling CL, Freedland SJ (2010) Statin medication use and the risk of biochemical recurrence after radical prostatectomy: results from the shared equal access regional cancer hospital (SEARCH) database. Cancer 116(14): 3389-3398. doi: 10. 1002/cncr. 25308.
10. Merseburger AS, Anastasiadis AG, Hennenlotter J, Schilling D, Simon P, Machtens SA, Serth J, Stenzl A, Kuczyk MA (2006) Tissue microarrays: applications in urological cancer research. World J Urol 24(5): 579-584. doi: 10. 1007/s00345-006-0103-1.
11. Remmele W, Stegner HE (1987) Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue. Pathologe 8(3): 138-140.
12. Mottet N, Bellmunt J, Bolla M, Joniau S, Mason M, Matveev V, Schmid HP, van der Kwast T, Wiegel T, Zattoni F, Heidenreich A (2011) EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol 59(4): 572-583. doi: 10. 1016/j. eururo. 2011. 01. 025.
13. Gnant M, Mlineritsch B, Schippinger W, Luschin-Ebengreuth G, Postlberger S, Menzel C, Jakesz R, Seifert M, Hubalek M, Bjelic-Radisic V, Samonigg H, Tausch C, Eidtmann H, Steger G, Kwasny W, Dubsky P, Fridrik M, Fitzal F, Stierer M, Rucklinger E, Greil R, Marth C (2009) Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med 360(7): 679-691. doi: 10. 1056/NEJMoa0806285.
14. Morgan C, Lewis PD, Jones RM, Bertelli G, Thomas GA, Leonard RC (2007) The in vitro anti-tumour activity of zoledronic acid and docetaxel at clinically achievable concentrations in prostate cancer. Acta Oncol 46(5): 669-677. doi: 10. 1080/02841860600996447.
15. Neville-Webbe HL, Rostami-Hodjegan A, Evans CA, Coleman RE, Holen I (2005) Sequence- and schedule-dependent enhancement of zoledronic acid induced apoptosis by doxorubicin in breast and prostate cancer cells. Int J Cancer 113(3): 364-371. doi: 10. 1002/ijc. 20602.
16. Fournier P, Boissier S, Filleur S, Guglielmi J, Cabon F, Colombel M, Clezardin P (2002) Bisphosphonates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rats. Cancer Res 62(22): 6538-6544.
17. Sarker D, Reid AH, Yap TA, de Bono JS (2009) Targeting the PI3K/AKT pathway for the treatment of prostate cancer. Clin Cancer Res 15(15): 4799-4805. doi: 10. 1158/1078-0432. CCR-08-0125.
18. Lin JF, Lin YC, Lin YH, Tsai TF, Chou KY, Chen HE, Hwang TI (2011) Zoledronic acid induces autophagic cell death in human prostate cancer cells. J Urol 185(4): 1490-1496. doi: 10. 1016/j. juro. 2010. 11. 045.
19. Marra M, Salzano G, Leonetti C, Tassone P, Scarsella M, Zappavigna S, Calimeri T, Franco R, Liguori G, Cigliana G, Ascani R, La Rotonda MI, Abbruzzese A, Tagliaferri P, Caraglia M, De Rosa G (2011) Nanotechnologies to use bisphosphonates as potent anticancer agents: the effects of zoledronic acid encapsulated into liposomes. Nanomedicine. doi: 10. 1016/j. nano. 2011. 03. 004.
20. Gonyeau MJ, Yuen DW (2010) A clinical review of statins and cancer: helpful or harmful? Pharmacotherapy 30(2): 177-194. doi: 10. 1592/phco. 30. 2. 177.
21. Boudreau DM, Yu O, Buist DS, Miglioretti DL (2008) Statin use and prostate cancer risk in a large population-based setting. Cancer Causes Control 19(7): 767-774. doi: 10. 1007/s10552-008-9139-4.
22. Soto DE, Daignault S, Sandler HM, Ray ME (2009) No effect of statins on biochemical outcomes after radiotherapy for localized prostate cancer. Urology 73(1): 158-162. doi: 10. 1016/j. urology. 2008. 02. 055.
23. Friedman GD, Flick ED, Udaltsova N, Chan J, Quesenberry CP Jr, Habel LA (2008) Screening statins for possible carcinogenic risk: up to 9 years of follow-up of 361, 859 recipients. Pharmacoepidemiol Drug Saf 17(1): 27-36. doi: 10. 1002/pds. 1507.
24. Bonovas S, Filioussi K, Sitaras NM (2008) Statin use and the risk of prostate cancer: a metaanalysis of 6 randomized clinical trials and 13 observational studies. Int J Cancer 123(4): 899-904. doi: 10. 1002/ijc. 23550.
25. Notarnicola M, Messa C, Cavallini A, Bifulco M, Tecce MF, Eletto D, Di Leo A, Montemurro S, Laezza C, Caruso MG (2004) Higher farnesyl diphosphate synthase activity in human colorectal cancer inhibition of cellular apoptosis. Oncology 67(5-6): 351-358. doi: 10. 1159/000082918.
26. Woo IS, Eun SY, Kim HJ, Kang ES, Lee JH, Chang KC, Kim JH, Hong SC, Seo HG (2010) Farnesyl diphosphate synthase attenuates paclitaxel-induced apoptotic cell death in human glioblastoma U87MG cells. Neurosci Lett 474(2): 115-120. doi: 10. 1016/j. neulet. 2010. 03. 021.
27. Jiang F, Yang L, Cai X, Cyriac J, Shechter I, Wang Z (2001) Farnesyl diphosphate synthase is abundantly expressed and regulated by androgen in rat prostatic epithelial cells. J Steroid Biochem Mol Biol 78(2): 123-130. doi: S0960-0760(01)00086-3.
28. Li J, Herold MJ, Kimmel B, Muller I, Rincon-Orozco B, Kunzmann V, Herrmann T (2009) Reduced expression of the mevalonate pathway enzyme farnesyl pyrophosphate synthase unveils recognition of tumor cells by Vγ9Vδ2 T cells. J Immunol 182(12): 8118-8124. doi: 10. 4049/jimmunol. 0900101.
29. Riddle MK, Lockhart AC, Sorscher SM (2010) Complete radiographic response to zoledronic acid therapy in a patient with bony metastatic urothelial carcinoma: a case report. World J Oncol 1(1): 208-209.
30. Sorscher SM, Lockhart AC (2011) Ras inhibition and the survival benefit favoring zoledronic acid compared with denosumab in patients with multiple myeloma. J Clin Oncol 29(19): 2735-2736. doi: 10. 1200/JCO. 2011. 35. 8333; Author reply 2736-2738.